Providers

Nearly 1 in 3 women aged 21 to 29 and 1 in 7 aged 30 to 65 had never been screened for cervical cancer by 2023.

There are significant, and uneven, knowledge gaps among physicians treating patients with mantle cell lymphoma and chronic lymphocytic leukemia across countries and settings, a survey finds.

Orbital rhabdomyosarcoma survival held steady despite less-intensive chemo and radiation, according to 25-year data.

AI-driven platform boosts screening capacity 41%, cuts manual review by 75% across Ochsner's 47 hospitals and 370 clinics.

Clinicians at a Chicago Population Health Roundtable say atopic dermatitis biologic therapy is delayed by several key obstacles.

Roundtable reveals vitiligo care gaps: Opzelura leads, insurers still call it cosmetic, and pricey oral JAKs near approval—what’s next?

A national survey finds retina specialists tolerate higher GA treatment risks in exchange for greater lesion growth rate reduction.

DLBCL expert Lunning weighs radiation consolidation after R-CHOP and spotlights Epkinly and SKYGLO bispecific trials, plus access and infection risks.

Clinicians spotlight issues that stall pediatric atopic dermatitis escalation and biologic therapy access, despite worsening disease burden.

After CAR T-cell therapy relapse in mantle cell lymphoma, an antibody drug conjugate regimen adapted from DLBCL shows durable remission.

Matched real-world MCL data shows acalabrutinib and zanubrutinib lower atrial fibrillation vs ibrutinib, with fewer bleeding events.

How tebentafusp, a BiTE bispecific T-cell engager, changes metastatic uveal melanoma care—HLA testing, dosing, safety and access tips for clinics.

Oral zasocitinib delivered skin clearance once limited to injectable biologics in phase 3 psoriasis trials, including hard-to-treat sites.

Shahzad Mian, MD, explains dry eye disease symptoms, key risk factors, and practical management strategies like drops and warm compresses.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

Women with PMOS had more than 4 times the adjusted ASCVD risk of matched peers, and traditional risk factors explained only about a third of the gap.

AI-guided breast screening is advancing faster than coverage policy, guidelines, and imaging capacity—raising questions about who qualifies and who pays.

GLP-1 use in adolescents and young adults with obesity rose to 96.1% as bariatric surgery fell by two-thirds, new JAMA Pediatrics data show.

Case series suggests glofitamab bridges relapsed mantle cell lymphoma to CAR T, with strong responses and mostly low-grade CRS.

New data suggest epcoritamab plus R2 may win insurer coverage, delivering major QALY gains at approximately $68,000 and delaying costly progression.

US drug shortages rose to 227 in Q2 2026, led by a severe ifosfamide shortage.

This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited patient involvement, and barriers to care coordination.

SNAP participation was linked to a smaller colorectal cancer screening gap among food-insecure US adults, ananalysis of 251,000 found.

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.